Show simple item record

dc.contributor.authorMohn, Kristin Greve-Isdahl
dc.contributor.authorBredholt, Geir
dc.contributor.authorZhou, Fan
dc.contributor.authorMadsen, Anders Aasgaard
dc.contributor.authorOnyango, Therese Bredholt
dc.contributor.authorFjelltveit, Elisabeth Berg
dc.contributor.authorJalloh, Sarah Larteley Lartey
dc.contributor.authorBrokstad, Karl Albert
dc.contributor.authorCantoni, Diego
dc.contributor.authorMayora-Neto, Martin
dc.contributor.authorTemperton, Nigel
dc.contributor.authorLangeland, Nina
dc.contributor.authorCox, Rebecca Jane
dc.description.abstractBackground Neutralizing antibodies are important for protection against the pandemic SARS-CoV-2 virus, and long-term memory responses determine the risk of re-infection or boosting after vaccination. T-cellular responses are considered important for partial protection against novel variants of concern. Methods A prospective cohort of hospitalized (n = 14) and community (n = 38) patients with rt-PCR confirmed SARS-CoV-2 infection were recruited. Blood samples and clinical data were collected when diagnosed and at 6 months. Serum samples were analyzed for SARS-CoV-2-spike specific antibodies using ELISA (IgG, IgA, IgM), pseudotype neutralization and microneutralization assays. Peripheral blood mononuclear cells were investigated for virus-specific T-cell responses in the interferon-γ and interleukin-2 fluorescent-linked immunosorbent spot (FluroSpot) assay. Results We found durable SARS-CoV-2 spike- and internal protein specific T-cellular responses in patients with persistent antibodies at 6 months. Significantly higher IL-2 and IFN-γ secreting T-cell responses as well as SARS-CoV-2 specific IgG and neutralizing antibodies were detected in hospitalized compared to community patients. The immune response was impacted by age, gender, comorbidity and severity of illness, reflecting clinical observations. Conclusions SARS-CoV-2 specific T-cellular and antibody responses persisted for 6 months post confirmed infection. In previously infected patients, re-exposure or vaccination will boost long-term immunity, possibly providing protection against re-infection with variant viruses.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleDurable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patientsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.journalPLOS ONEen_US
dc.identifier.citationPLOS ONE. 2022, 17 (2), e0261979.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal